DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Media formats available
Completing the pre-test is required to access this content.
Pre-Survey
Completing the pre-survey is required to access this content.
